The medical trial shall assess the investigational TB drug developed by AstraZeneca, based in London. In laboratory tests, the drug proved active against an array of drug-delicate and drug-resistant strains of Mycobacterium tuberculosis , the bacterium that causes TB disease. In two preliminary human being studies in the United States, testing multiple doses, the oral medication was well-tolerated generally. Some scholarly study participants experienced gastrointestinal and blood-related adverse occasions at higher doses, but these results were reversible rather than significant.The scholarly study authors say the findings, which echo other recent studies, may be a complete result of patients becoming more sensitive to absorbing alcoholic beverages following the procedure, or because they go from getting socially isolated while overweight to presenting a more active, alcohol-filled social life. Despite the risks, the procedure may provide long-term weight loss. It could also treat or cure obesity-related circumstances such as gastroesophageal reflux disease , heart disease, high blood pressure, sleep apnea and Type 2 diabetes, according to the Mayo Clinic. A study in March 2012 discovered diabetics who underwent the medical procedures could actually stop taking insulin as soon as three days following the medical procedures, or went into total disease remission for at least 2 yrs.